杨贵妃传媒視頻

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 杨贵妃传媒視頻 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jan 17 2024

Full Issue

ResMed Respiratory Masks With Magnets Stay On Sale Despite Recall

The mask recall had been classified as "most serious" by the FDA because of the risk of injury or death. But ResMed argued the issue centers on a labeling matter and is not a product removal. Separately, a CRISPR gene therapy for sickle cell can be used on a different disorder, the FDA said.

ResMed said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug Administration classified a recall of the product as most serious as their use could cause major injuries or death. The California-based medical device maker, which started the recall process on Nov. 20, said the classification was due to a correction in the labeling and is not a product removal. (1/16)

In other pharmaceutical news 鈥

A therapy based on CRISPR gene-editing technology that the Food and Drug Administration approved in December for sickle cell disease can be used for a second inherited blood disorder, the agency said on Tuesday. (Bettelheim, 1/17)

When Kelsey Brown met Mohammed, the 15-year-old Ugandan boy looked terribly worried. He was in the late stages of rheumatic heart disease, which kills about 400,000 people a year worldwide. His scheduled heart surgery to address the illness had been postponed a day. By this point, fluid that backed up from Mohammed鈥檚 heart into his lungs made it so hard to breathe that he had to sleep sitting upright. Brown, a cardiology fellow at Children鈥檚 National Hospital in Washington, assumed that he was anxious about undergoing the surgery. But Mohammed told her that he was not scared to face the procedure. (Johnson, 1/16)

The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The intervention her doctors offered to prevent the hair loss was a cold cap that, cooled to 32 degrees Fahrenheit, would turn her scalp into an icy crown. But, to her, it wasn鈥檛 much of an option. (Chen, 1/17)

Washington University has joined up with a New York investment firm to launch a new drug research and development business, the school announced Tuesday. Deerfield Management Co. has committed up to $130 million over the next decade. The new company will be called VeritaScience, a nod to the university鈥檚 motto, 鈥淧er Veritatem Vis,鈥 or 鈥淪trength Through Truth.鈥 (Merrilees, 1/16)

More than half of those responsible for registering clinical trials and reporting results fail to do so over confusion about key requirements, according to a new survey that highlighted ongoing difficulties in achieving transparency surrounding study data. (Silverman, 1/16)

杨贵妃传媒視頻 Health News: Listen To The Latest '杨贵妃传媒視頻 Health News Minute'聽

This week on the 杨贵妃传媒視頻 Health News Minute: A national shortage of Adderall leaves people with narcolepsy struggling to live normal lives. and researchers find little evidence that mental health courts are keeping those who need them most out of lockup. (1/16)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
  • Thursday, May 21
More Morning Briefings
RSS Feeds
  • 杨贵妃传媒視頻
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF